A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease

Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease-small cell lung cancer (ED- SCLC): Final results of a randomised phase III trial

(2017) D. F. Heigener et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

(2009) Primo N. Lara et al.   JOURNAL OF CLINICAL ONCOLOGY

Small Cell Lung Cancer

(2009) Taimur Sher et al.   MAYO CLINIC PROCEEDINGS

Irinotecan Plus Carboplatin Versus Oral Etoposide Plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial

(2008) Andreas Hermes et al.   JOURNAL OF CLINICAL ONCOLOGY

Third-Generation Chemotherapy Agents in the Treatment of Advanced Non-small Cell Lung Cancer: A Meta-Analysis

(2008) Thomas E. Stinchcombe et al.   Journal of Thoracic Oncology

Third-Generation Chemotherapy Agents in the Treatment of Advanced Non-small Cell Lung Cancer: A Meta-Analysis

(2008) Jean-Paul Sculier et al.   Journal of Thoracic Oncology